These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27129876)

  • 1. p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis.
    Du J; Wang SH; Yang Q; Chen QQ; Yao X
    World J Surg Oncol; 2016 Apr; 14():137. PubMed ID: 27129876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 Status correlates with the risk of recurrence in non-muscle invasive bladder cancers treated with Bacillus Calmette-Guérin: a meta-analysis.
    Zhou X; Zhang G; Tian Y
    PLoS One; 2015; 10(3):e0119476. PubMed ID: 25742650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome.
    Lacombe L; Dalbagni G; Zhang ZF; Cordon-Cardo C; Fair WR; Herr HW; Reuter VE
    J Clin Oncol; 1996 Oct; 14(10):2646-52. PubMed ID: 8874323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors including Ki-67 and p53 in Bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer: a prospective study.
    Oderda M; Ricceri F; Pisano F; Fiorito C; Gurioli A; Casetta G; Zitella A; Pacchioni D; Gontero P
    Urol Int; 2013; 90(2):184-90. PubMed ID: 23328160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and RB expression predict progression in T1 bladder cancer.
    Grossman HB; Liebert M; Antelo M; Dinney CP; Hu SX; Palmer JL; Benedict WF
    Clin Cancer Res; 1998 Apr; 4(4):829-34. PubMed ID: 9563875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer.
    Gaya JM; López-Martínez JM; Karni-Schmidt O; Bonal DM; Algaba F; Palou J; Villavicencio H; Benson MC; Cordon-Cardo C; Castillo-Martin M
    J Urol; 2015 Apr; 193(4):1144-50. PubMed ID: 25444981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of p53 overexpression in bladder tumors treated with Bacillus Calmette-Guerin.
    Peyromaure M; Ravery V
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):667-70. PubMed ID: 12503212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
    Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
    Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
    Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
    BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
    Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
    Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
    Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
    J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
    van Rhijn BW; Liu L; Vis AN; Bostrom PJ; Zuiverloon TC; Fleshner NE; van der Aa MN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Bapat B; van der Kwast TH; Zlotta AR
    BJU Int; 2012 Oct; 110(8):1169-76. PubMed ID: 22448597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 as a prognostic marker for bladder cancer: a meta-analysis and review.
    Malats N; Bustos A; Nascimento CM; Fernandez F; Rivas M; Puente D; Kogevinas M; Real FX
    Lancet Oncol; 2005 Sep; 6(9):678-86. PubMed ID: 16129368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.